June 20 , 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform™ (deuterated chemical entity platform). CTP-499 is progressing into …
Concert Pharmaceuticals Announces Milestone Achievement in GlaxoSmithKline Collaboration
June 20 , 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. today announced that it has achieved a milestone in its strategic alliance with GlaxoSmithKline (GSK) for its HIV protease inhibitor …
Concert Pharmaceuticals Expands Regulatory and Clinical Leadership with New Appointments
Mark Roessel Named Vice President of Regulatory Affairs and Quality Assurance LuAnn Sabounjian Named Vice President, Clinical Operations April 12 , 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. …
Concert Pharmaceuticals Advances Novel Chronic Kidney Disease Treatment, CTP-499, in Phase 1 Clinical Study
First-in-Class Drug Candidate from Deuterium Platform Has Anti-Inflammatory, Anti-Fibrotic, and Anti-Oxidant Properties March 29 , 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. today announced …
Concert Pharmaceuticals Enters Into a Cooperative Research and Development Agreement with Walter Reed Army Institute of Research to Evaluate Neuroprotective Drug Compound
Advances Concert’s R&D for Novel Drugs to Treat Seizure-Generating Diseases and Injuries February 2, 2011 Lexington, MA -- Concert Pharmaceuticals, Inc. today announced that it has entered into a …
James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals
Additional Management Team Announcement with Promotion of Robert Silverman January 19, 2011, Lexington, MA -- Concert Pharmaceuticals, Inc. announced today the appointment of James E. Shipley, M.D., …
New Patents Continue to issue for Concert Pharmaceuticals Deuterium Chemistry Intellectual Property
January 13, 2011 Lexington, MA –- Concert Pharmaceuticals, Inc. announced the issuance of several new patents relating to specific compounds derived from its DCE Platform™ (Deuterated Chemical Entity …